Martingale Asset Management’s Halozyme HALO Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2023
Q2
Sell
-15,021
Closed -$574K 836
2023
Q1
$574K Buy
15,021
+901
+6% +$42.3K 0.01% 588
2022
Q4
$803K Buy
14,120
+1,303
+10% +$66.7K 0.02% 522
2022
Q3
$507K Buy
12,817
+7,597
+146% +$336K 0.01% 621
2022
Q2
$230K Buy
+5,220
New +$226K ﹤0.01% 786

Other funds holding HALO

Martingale Asset Management's HALO Position: Q2 2023 in Review

Martingale Asset Management sold out of Halozyme (HALO) in Q2 2023, closing a stake of 15,021 shares — an estimated $574K sold.

Martingale Asset Management first reported a position in HALO in Q2 2022 and held it in 4 quarters. The position peaked at $803K in Q4 2022. 370 funds tracked by Wall St. Rank hold HALO as of Q2 2023.

  • Martingale Asset Management reported no remaining Halozyme position as of Q2 2023 after selling out during the quarter.
  • Martingale Asset Management sold 15,021 Halozyme shares in Q2 2023, an estimated $574K.
  • Martingale Asset Management first reported a position in Halozyme in Q2 2022 and held it in 4 quarters.
  • Martingale Asset Management's Halozyme position peaked at $803K in Q4 2022.
  • 370 funds tracked by Wall St. Rank held Halozyme as of Q2 2023.

Based on Martingale Asset Management's 13F filing for Q2 2023, filed 11 Aug 2023.